Altimmune ($ALT) shares surged 16% premarket following stellar Phase 2b data for pemvidutide, its dual-action MASH treatment. The 48-week trial showed significant liver fat reduction and weight loss, outperforming placebos. With a successful FDA meeting clearing the path for a Phase 3 trial and no weight-loss plateau in sight, investors are betting on this being a major liver disease disruptor.